NCT01339637已完成不适用
Evaluation of Low Source of Signal in SCOUT DS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 196
- 试验地点
- 2
- 主要终点
- Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals
研究概览
简要总结
The overall objective of this study is to increase the number of dark skin tone individuals in the data set and evaluate if this increase in dark skin tone data has an impact on the accuracy of the SCOUT DS Diabetes Risk Score (DRS).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dark Skin Tone (Von Luschan chromatic skin color > 35)
- •Age greater than or equal to 45 years;
- •Age 18 to 44 years and a BMI > 25 kg/m² with one or more of the following diabetes risk factors:
- •Habitually physically inactive (less than 30 minutes of moderate physical activity most, if not all, days of the week)
- •Has a first-degree relative with type 2 diabetes
- •African American, Latino, Native American, Asian American, Pacific Islander
- •Has delivered a baby weighing > 9 lb or previously diagnosed with gestational diabetes
- •Hypertension (≥140/≥ 90 mmHg) or being treated for hypertension
- •HDL cholesterol level < 35 mg/dL and/or a fasting triglyceride level ≥ 250 mg/dL or being treated for dyslipidemia with medication
- •Has been previously diagnosed with Polycystic Ovary Syndrome (PCOS)
- •Had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 years
- •Conditions associated with insulin resistance such as severe obesity or acanthosis nigricans
- •History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease
排除标准
- •Prior participation under VeraLight protocols: VL-2710, VL-2711 or VL-2712
- •Under 18 years of age
- •Receiving investigational treatments in the past 14 days
- •Psychosocial issues that interfere with an ability to follow study procedures
- •Conditions that cause secondary diabetes including Cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis
- •Diagnosed with any type of diabetes, including type 1 or 2
- •Taking glucose lowering medications
- •Known to be pregnant
- •Receiving dialysis or having known renal compromise
- •Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
- •Recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded
- •Current chemotherapy, or chemotherapy within the past 12 months
- •Receiving medications that fluoresce*
- •Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
- •Known to have, or at risk for, sensitivity to skin lotions or shaving (creams, lotions, soap, shaving cream)
- •Prior bariatric surgery
结局指标
主要结局
Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals
时间窗: 6 months
The primary study endpoint is the relative true positive and relative true negative fractions between the SCOUT DS and FPG test for detecting abnormal glucose tolerance (2 hr OGTT value ≥ 140 mg/dL).
次要结局
- Compare SCOUT DS and FPG to HbA1c(6 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Role of Color Doppler Ultrasonography in Assessment of Vascular Access Surveillance in Hemodialysis Patients.Arteriovenous FistulaNCT04196478Assiut University120
已完成
2 期
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell CaCarcinoma, Squamous CellHead and Neck NeoplasmsOropharyngeal NeoplasmsNCT01530997UNC Lineberger Comprehensive Cancer Center45
已完成
不适用
LLLT for Reducing Waste Circumference and WeightWeight LossNCT02877004Mayo Clinic60
招募中
不适用
TransCranial Doppler for REDUCtion of Silent strokE During MitraClip ImplantationMitral Valve InsufficiencyNCT04384198Charite University, Berlin, Germany32
已完成
不适用
Transcranial Direct Current Stimulation for Primary Progressive AphasiaPrimary Progressive AphasiaNCT02928848University of Pennsylvania16